NYMC Faculty Publications

Triggering Final Oocyte Maturation With Gonadotropin-Releasing Hormone Agonist (GnRHa) Versus Human Chorionic Gonadotropin (hCG) in Breast Cancer Patients Undergoing Fertility Preservation: An Extended Experience

Author Type(s)

Faculty

DOI

10.1007/s10815-014-0248-6

Journal Title

Journal of Assisted Reproduction and Genetics

First Page

927

Last Page

932

Document Type

Article

Publication Date

7-1-2014

Department

Obstetrics and Gynecology

Keywords

Adult, Anti-Mullerian Hormone, Breast Neoplasms, Chorionic Gonadotropin, Female, Fertility Preservation, Gonadotropin-Releasing Hormone, Humans, In Vitro Oocyte Maturation Techniques, Letrozole, Nitriles, Ovarian Hyperstimulation Syndrome, Ovulation Induction, Triazoles

Disciplines

Medicine and Health Sciences

Abstract

PURPOSE: To analyze the cycle outcomes and the incidence of ovarian hyperstimulation syndrome (OHSS), when oocyte maturation was triggered by gonadotropin-releasing hormone agonist (GnRHa) versus human chorionic gonadotropin (hCG) in breast cancer patients undergoing fertility preservation.

METHODS: One hundred twenty-nine women aged ≤ 45 years, diagnosed with stage ≤ 3 breast cancer, with normal ovarian reserve who desired fertility preservation were included in the retrospective cohort study. Ovarian stimulation was achieved utilizing letrozole and gonadotropins. Oocyte maturation was triggered with GnRHa or hCG. Baseline AMH levels, number of oocytes, maturation and fertilization rates, number of embryos, and the incidence of OHSS was recorded.

RESULTS: The serum AMH levels were similar between GnRHa and hCG groups (2.7 ± 1.9 vs. 2.1 ± 1.8; p = 0.327). There was one case of mild or moderate OHSS in the GnRHa group compared to 12 in the hCG group (2.1 % vs. 14.4 %, p = 0.032). The maturation and fertilization rates, and the number of cryopreserved embryos were significantly higher in the GnRHa group.

CONCLUSIONS: GnRHa trigger improved cycle outcomes as evidenced by the number of mature oocytes and cryopreserved embryos, while significantly reducing the risk of OHSS in breast cancer patients undergoing fertility preservation.

Link to Full Text

Share

COinS